<![CDATA[ AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)]]>https://aidsinfo.nih.gov/e-news/archive60<![CDATA[AIDSinfo Releases Brief Versions of the HIV/AIDS Medical Practice Guidelines]]>https://aidsinfo.nih.gov/e-news/archive/2018/11/13info is pleased to announce the release of brief versions of the federally approved HIV/AIDS medical practice guidelines. Health care providers have requested shorter versions of the guidelines that are easier to use at the point of care, and AIDSinfo used this feedback to produce brief versions of the following guidelines:

The brief versions contain only the Panel’s recommendations and tables, allowing health care providers to quickly locate relevant information when caring for people with HIV. They are easily accessed by selecting the Brief Guidelines tab at the top of each guideline section.

AIDSinfo welcomes your feedback on the brief guidelines. Please email your comments or questions to ContactUs@aidsinfo.nih.gov.


Tue, 13 Nov 2018 00:00:00 -0500
<![CDATA[ Adult and Adolescent Opportunistic Infections Guidelines Updated]]>https://aidsinfo.nih.gov/e-news/archive/2018/11/13Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents were updated on November 13, 2018:
  • Hepatitis B Virus Infection: The panel added information regarding the recently approved two-dose hepatitis B vaccine conjugated to a TLR9 agonist (Heplisav-B). Since there are no data on this vaccine in HIV-infected individuals, the panel presents it as an option with a CIII recommendation. The panel added recommendations regarding considerations to prevent HBV reactivation during immunosuppressive therapy in patients with HBsAg-negative/anti-HBc positive disease, which include starting tenofovir/emtricitabine backbone when possible with other options presented if this cannot be given.
  • Progressive Multifocal Leukoencephalopathy/JC Virus Infection: The section was updated to reflect current information about the value of plasma PCR and to include updated references on failed therapies.
Tue, 13 Nov 2018 00:00:00 -0500
<![CDATA[HHS Adult and Adolescent Antiretroviral Treatment Guidelines Updated]]>https://aidsinfo.nih.gov/e-news/archive/2018/10/25The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents has released an updated version of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.

Key changes to the guidelines include the following:
  • Preliminary data suggest that there is an increased risk of neural tube defects in infants born to women who were receiving the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) at the time of conception. In response, several sections in the Adult and Adolescent Antiretroviral (ARV) Guidelines have been updated to provide guidance for clinicians who are considering the use of DTG or other INSTIs in individuals who are pregnant, or in those of childbearing potential who plan to get pregnant or who are sexually active and not using effective contraception.
  • Several changes have been made to the recommendations for initial ARV regimens in the What to Start section.
  • Bictegravir is a new INSTI that is approved by the Food and Drug Administration (FDA) as part of the single-tablet regimen bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC). This regimen is classified as a Recommended Initial Regimen for Most People with HIV.
  • Doravirine, a new non-nucleoside reverse transcriptase inhibitor, was recently approved by the FDA. The single-tablet regimen doravirine/tenofovir disoproxil fumarate/lamivudine (DOR/TDF/3TC) and DOR plus TAF/FTC have been classified as Recommended Initial Regimens in Certain Clinical Situations.
  • The two-drug regimen DTG plus 3TC is now one of the regimens to consider when abacavir, TAF, or TDF cannot be used or are not optimal.
  • New information has been added to the Drug-Resistance Testing section regarding the use of HIV-1 proviral DNA genotypic resistance tests to identify drug resistance mutations, especially in the setting of low-level viremia or when plasma HIV RNA is below the limit of detection.
  • The Virologic Failure section now includes a review of clinical trial data on the use of ibalizumab, a newly approved CD4 post-attachment inhibitor, in persons with multidrug-resistant HIV.
  • The title of the Regimen Switching in the Setting of Virologic Suppression section has been changed to Optimizing Antiretroviral Therapy in the Setting of Viral Suppression to better reflect the rationale for regimen changes in this setting.
  • The Exposure-Response Relationship and Therapeutic Drug Monitoring section has been removed from the guidelines. The subsection regarding the role of therapeutic drug monitoring in managing drug-drug interactions has been moved to the Drug-Drug Interactions section of the guidelines.
  • Several tables in the guidelines have been updated with new data, as well as information related to BIC and DOR.

For a complete list of guideline updates, please see What's New in the Guidelines. Additions and revisions are also highlighted in yellow throughout the PDF version of the guidelines.

To view or download the guidelines, go to the Adult and Adolescent ARV Guidelines section of AIDSinfo’s website. The guideline tables and the boxed recommendations can also be downloaded as separate PDF files.

Send Comments on the Revised Guidelines to AIDSinfo

Feedback on the revised Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV is welcome. Please email your comments with the subject line “Comments on the Adult and Adolescent ARV Guidelines” to ContactUs@aidsinfo.nih.gov by November 8, 2018.

Thu, 25 Oct 2018 00:00:00 GMT
<![CDATA[Explore Spanish-Language HIV Resources on infoSIDA]]>https://aidsinfo.nih.gov/e-news/archive/2018/10/18infoSIDA offers HIV-related health information in Spanish? infoSIDA is AIDSinfo’s Spanish-language companion website and offers the same educational resources found on AIDSinfo:
In addition, the AIDSinfo Drug Database and Glossary apps provide information in both English and Spanish.

infoSIDA is a valuable resource for anyone looking for HIV-related information in Spanish, including health care providers with Spanish-speaking patients. Visit infoSIDA to view the Spanish-language resources and download the apps.]]>
Thu, 18 Oct 2018 00:00:00 GMT
<![CDATA[View New and Updated HIV Drug Fact Sheets on AIDSinfo]]>https://aidsinfo.nih.gov/e-news/archive/2018/10/4

AIDSinfo recently published a number of new and updated drug fact sheets. These include fact sheets for two new antiretroviral (ARV) medications recently approved by the Food and Drug Administration (FDA), as well as new and updated investigational drug fact sheets.

New FDA-Approved ARV Drug Fact Sheets: New Investigational Drug Fact Sheets: Recently Updated Investigational Drug Fact Sheets:

Visit infoSIDA to view the drug fact sheets in Spanish.

Thu, 4 Oct 2018 00:00:00 GMT
<![CDATA[ October 15 is National Latinx AIDS Awareness Day]]>https://aidsinfo.nih.gov/e-news/archive/2018/10/4

According to the Centers for Disease Control and Prevention (CDC), in 2016, Hispanics/Latinos accounted for 26% of new diagnoses of HIV in the United States and 6 dependent areas. Stigma, language barriers, and limited access to health care are among the factors that contribute to the higher rates of HIV infection in Hispanic/Latino communities.

October 15 is National Latinx AIDS Awareness Day—a day to raise awareness and promote prevention and treatment of HIV in the Hispanic/Latino community. To learn more, visit the AIDSinfo National Latinx AIDS Awareness Day webpage [en español].

Thu, 4 Oct 2018 00:00:00 GMT
<![CDATA[ Recent HIV News from NIH]]>https://aidsinfo.nih.gov/e-news/archive/2018/10/4
  • September 19, 2018: NIH Funds Study to Prevent, Treat HIV Among Adolescents in Poor Countries
  • September 20, 2018: NIH Launches Study to Test Combination Antibody Treatment for HIV Infection
  • September 26, 2018: Combination HIV Antibody Infusions Safely Maintain Viral Suppression in Select Individuals
  • ]]>
    Thu, 4 Oct 2018 00:00:00 GMT